{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:25:51Z","timestamp":1784863551734,"version":"3.55.0"},"reference-count":26,"publisher":"Akademiai Kiado Zrt.","issue":"23","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,6,11]]},"abstract":"<jats:p><jats:italic>Bevezet\u00e9s:<\/jats:italic> A myeloma multiplex az egyik leggyakoribb\n                    hematol\u00f3giai malignit\u00e1s, \u00e9vi kb. 400 esettel Magyarorsz\u00e1gon. Az ut\u00f3bbi\n                    \u00e9vtizedben bevezetett \u00faj gy\u00f3gyszerek sokat jav\u00edtottak a legt\u00f6bb beteg t\u00fal\u00e9l\u00e9s\u00e9n,\n                    azok azonban, akik az els\u0151 vonalbeli kezel\u00e9sre nem j\u00f3l reag\u00e1lnak, \u00e9s nem\n                    juttathat\u00f3k \u0151ssejt-transzplant\u00e1ci\u00f3ra, igen rossz progn\u00f3zissal n\u00e9znek szembe. A\n                    szelekt\u00edv Bcl-2-inhibitor venetoclax rendk\u00edv\u00fcl hat\u00e1sosnak bizonyult\n                    relab\u00e1lt\/refrakter betegekben, m\u00e1sodik vonalban, ment\u0151kezel\u00e9sk\u00e9nt val\u00f3\n                    alkalmaz\u00e1s\u00e1r\u00f3l azonban kev\u00e9s az adat. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Kutat\u00e1sunk\n                    c\u00e9lja a Klinik\u00e1nkon venetoclax ment\u0151kezel\u00e9sben r\u00e9szes\u00fclt t(11;14)-betegek\n                    adatainak elemz\u00e9se \u00e9s a ter\u00e1pia hat\u00e9konys\u00e1g\u00e1nak \u00e9rt\u00e9kel\u00e9se volt.\n                        <jats:italic>M\u00f3dszer:<\/jats:italic> 2017 \u00e9s 2021 k\u00f6z\u00f6tt 13 beteg eset\u00e9ben alkalmaztunk\n                    a frontline kezel\u00e9sre adott szuboptim\u00e1lis v\u00e1lasz miatt venetoclaxkezel\u00e9st,\n                    adataikat retrospekt\u00edven elemezt\u00fck. <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    Betegcsoportunkban nagyon gyakoriak voltak az adverz prognosztikai faktorok:\n                    del(17p) 4 betegn\u00e9l, amp(1q21) 5 betegn\u00e9l, m\u00edg 3. st\u00e1dium 6 betegn\u00e9l volt jelen.\n                    Ennek ellen\u00e9re mind a 13 beteg kiv\u00e1l\u00f3an reag\u00e1lt a venetoclaxter\u00e1pi\u00e1ra, 6 nagyon\n                    j\u00f3 parci\u00e1lis v\u00e1laszt, 7 pedig komplett v\u00e1laszt \u00e9rt el. Minden alkalmas beteget\n                    transzplant\u00e1ci\u00f3ra tudtunk juttatni. Medi\u00e1n 38 h\u00f3napos k\u00f6vet\u00e9s ut\u00e1n sem a medi\u00e1n\n                    progresszi\u00f3mentes, sem a medi\u00e1n teljes t\u00fal\u00e9l\u00e9st nem \u00e9rt\u00fck el, csup\u00e1n 3 beteg\n                    progredi\u00e1lt, \u00e9s 1-et vesz\u00edtett\u00fcnk el. <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Vizsg\u00e1latunk azt mutatta, hogy a standard korai ter\u00e1pi\u00e1ra szuboptim\u00e1lisan\n                    reag\u00e1l\u00f3 \u00e9s ment\u0151kezel\u00e9sre szorul\u00f3 t(11;14)-betegek eset\u00e9ben a venetoclax\n                    k\u00fcl\u00f6n\u00f6sen j\u00f3 kezel\u00e9si opci\u00f3. Orv Hetil. 2023; 164(23): 894\u2013899.<\/jats:p>","DOI":"10.1556\/650.2023.32790","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T12:41:50Z","timestamp":1686573710000},"page":"894-899","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":4,"title":["Venetoclaxalap\u00fa ment\u0151kezel\u00e9s (11;14)-transzlok\u00e1ci\u00f3s myeloma multiplexben az els\u0151 vonalbeli kezel\u00e9sre adott nem megfelel\u0151 v\u00e1lasz eset\u00e9n"],"prefix":"10.1556","volume":"164","author":[{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Syoreni","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Ruff","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Ga\u00e1l","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Varga G, Mikala G, V\u00e1r\u00f3czy L, et al. Management of multiple myeloma in Hungary in 2016. [A myeloma multiplex megk\u00f6zel\u00edt\u00e9se Magyarorsz\u00e1gon 2016-ban.] Orv Hetil. 2016; 157: 123-137. [Hungarian]","DOI":"10.1556\/650.2016.30341"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2 Moreau P, Attal M, P\u00e9gouri\u00e9 B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011; 117: 3041-3044. Erratum: Blood 2012; 120: 4274.","DOI":"10.1182\/blood-2012-10-463661"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2011.051441","article-title":"Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease","volume":"97","author":"3 Rosi\u00f1ol","year":"2012","unstructured":"3 Rosi\u00f1ol L, Garc\u00eda-Sanz R, Lahuerta JJ, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 2012; 97: 616-621.","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"4 Vij","year":"2015","unstructured":"4 Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015; 21: 335-341.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1080\/10428194.2020.1788014","article-title":"Primary refractory multiple myeloma: a real-world experience with 85 cases","volume":"61","author":"5 Jurczyszyn","year":"2020","unstructured":"5 Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, et al. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma 2020; 61: 2868-2875.","journal-title":"Leuk Lymphoma"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.24131","article-title":"Outcomes of primary refractory multiple myeloma and the impact of novel therapies","volume":"90","author":"6 Majithia","year":"2015","unstructured":"6 Majithia N, Rajkumar SV, Lacy MQ, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015; 90: 981-985.","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Gran C, Uttervall K, Borg Bruchfeld J, et al. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol. 2019; 103: 588-596.","DOI":"10.1111\/ejh.13325"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"8 Lakshman","year":"2018","unstructured":"8 Lakshman A, Alhaj Moustafa M, Rajkumar SV, et al. Natural history of t(11;14) multiple myeloma. Leukemia 2018; 32: 131-138.","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Lim KJ, Talaulikar D, Tan JLC, et al. Inferior outcomes for multiple myeloma (MM) patients (pts) harbouring t(11;14) and the promise of venetoclax, real-world Australian retrospective. Blood 2021; 138(Suppl 1): 4752.","DOI":"10.1182\/blood-2021-145508"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"10 Turesson","year":"2018","unstructured":"10 Turesson I, Bjorkholm M, Blimark CH, et al. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018; 101: 237-244.","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"11 Kaufman","year":"2021","unstructured":"11 Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021; 96: 418-427.","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/bjh.16454","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"12 Basali","year":"2020","unstructured":"12 Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma. Br J Haematol. 2020; 189: 1136-1140.","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"13 Kumar","year":"2020","unstructured":"13 Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020; 21: 1630-1642.","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020; 95: E34-E35.","DOI":"10.1002\/ajh.25676"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"15 Bahlis","year":"2021","unstructured":"15 Bahlis NJ, Baz R, Harrison SJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021; 39: 3602-3612.","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Jelinek T, Mihalyova J, Kascak M, et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019; 94: E35-E37.","DOI":"10.1002\/ajh.25331"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"17 Kumar","year":"2017","unstructured":"17 Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 2017; 130: 2401-2409.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Premkumar V, Comenzo RL, Lentzsch S. Preliminary evidence of efficacy of venetoclax in relapsed and refractory AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2019; 19: e327-e328.","DOI":"10.1016\/j.clml.2019.09.538"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A phase II study of venetoclax in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"21","author":"19 Gasparetto","year":"2021","unstructured":"19 Gasparetto C, Bowles KM, Abdallah A-O, et al. A phase II study of venetoclax in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021; 21: 775-784.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Jackson GH, Davies FE, Pawlyn C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019; 6: e616-e629.","DOI":"10.1016\/S2352-3026(19)30167-X"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2021-146619","article-title":"Outcomes among primary refractory multiple myeloma patients in the era of monoclonal antibodies: the Yale experience","volume":"138","author":"21 Liu","year":"2021","unstructured":"21 Liu Y, Kywe B, Crawford L, et al. Outcomes among primary refractory multiple myeloma patients in the era of monoclonal antibodies: the Yale experience. Blood 2021; 138: 1635.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","article-title":"Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers","volume":"28","author":"22 Szita","year":"2022","unstructured":"22 Szita VR, Mikala G, Kozma A, et al. Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers. Pathol Oncol Res. 2022; 28: 1610276.","journal-title":"Pathol Oncol Res"},{"key":"ref22","unstructured":"23 Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17: e328-e346."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"24 Agarwal","year":"2017","unstructured":"24 Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017; 83: 846-854.","journal-title":"Br J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-134850","article-title":"CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study","volume":"136","author":"25 Jonas","year":"2020","unstructured":"25 Jonas BA, Dinardo CD, Fracchiolla N, et al. CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study. Blood 2020; 136: 50-52.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/cpt.712","article-title":"Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients","volume":"102","author":"26 Freise","year":"2017","unstructured":"26 Freise KJ, Jones AK, Verdugo ME, et al. Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clin Pharmacol Ther. 2017; 102: 970-976.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/23\/article-p894.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/23\/article-p894.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/23\/article-p894.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:43:00Z","timestamp":1697701380000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/23\/article-p894.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":26,"journal-issue":{"issue":"23"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32790","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,11]]}}}